symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
RUBY,0.01715,2.26374,75099,1551783,0,0.0032-0.4399,-0.0009,"Rubius Therapeutics, Inc.",USD,0001709401,US78116T1034,78116T103,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.rubiustx.com,"Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.",Dr. Laurence A. Turka M.D.,Healthcare,US,6,617 679 9600,399 Binney Street,Cambridge,MA,02139,2.5679,3.6379,https://financialmodelingprep.com/image-stock/RUBY.png,2018-07-18,False,False,True,False,False
